Trials / Recruiting
RecruitingNCT06978699
A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Multicenter, Randomized, Single-blind Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- S-INFINITY Pharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XH-S003 Capsule | 25mg \& 100mg |
Timeline
- Start date
- 2025-04-30
- Primary completion
- 2025-08-30
- Completion
- 2026-10-30
- First posted
- 2025-05-18
- Last updated
- 2025-05-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06978699. Inclusion in this directory is not an endorsement.